Baird raises Bio-Techne price target to $73
Baird analyst Catherine Schulte maintained a Neutral rating on Bio-Techne (NASDAQ: TECH) and raised the price target to $73 from $49, signaling a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Baird analyst Catherine Schulte has maintained a Neutral rating on Bio-Techne (NASDAQ: TECH) and increased the price target to $73 from the previous $49. The adjustment reflects a revised valuation outlook for the company.
Rating and Price Target Details
The research note updates the investment stance on Bio-Techne, keeping the recommendation at Neutral. The primary change involves the price objective, which has been adjusted upward significantly.
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $49 |
| New Price Target | $73 |
The revised target suggests a potential upside based on the current trading price, though the Neutral rating indicates a balanced risk-reward profile at this time.
What specific factors drove the significant upward revision in Bio-Techne's valuation outlook?
How might the Neutral rating impact investor sentiment despite the increased price target?
What upcoming catalysts could shift Bio-Techne's risk-reward profile from Neutral to a more bullish stance?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
